dc.contributor.author |
Zemanick, Edith |
|
dc.contributor.author |
Burgel, Pierre-Régis |
|
dc.contributor.author |
Taccetti, Giovanni |
|
dc.contributor.author |
Holmes, Alison |
|
dc.contributor.author |
Ratjen, Felix |
|
dc.contributor.author |
Byrnes, Catherine A |
|
dc.contributor.author |
Waters, Valerie J |
|
dc.contributor.author |
Bell, Scott C |
|
dc.contributor.author |
VanDevanter, Donald R |
|
dc.contributor.author |
Stuart Elborn, J |
|
dc.contributor.author |
Flume, Patrick A |
|
dc.contributor.author |
Antimicrobial Resistance International Working Group in Cystic Fibrosis |
|
dc.coverage.spatial |
Netherlands |
|
dc.date.accessioned |
2022-06-13T23:15:57Z |
|
dc.date.available |
2022-06-13T23:15:57Z |
|
dc.date.issued |
2020-05 |
|
dc.identifier.citation |
(2020). Journal of Cystic Fibrosis, 19(3), 370-375. |
|
dc.identifier.issn |
1569-1993 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/59813 |
|
dc.description.abstract |
<h4>Background</h4>Antimicrobial susceptibility testing (AST) is a cornerstone of infection management in cystic fibrosis. However, there is little evidence that AST predicts the clinical outcome of CF antimicrobial treatment. It has been suggested there is a need for careful consideration of current AST use by the CF community.<h4>Methods</h4>We engaged a group of experts consisting of pulmonary (adult and pediatric) and infectious disease clinicians, microbiologists, and pharmacists representing a broad international experience. We conducted an iterative systematic survey (Delphi) to determine and quantify consensus regarding key questions facing CF clinicians in the use of respiratory culture results including what tests to order, when to obtain them, and how to act upon the results of the testing.<h4>Results</h4>Consensus was reached for many questions but there was not universal agreement to the questions that were addressed. There were some differences with respect to cultures obtained for surveillance compared to when there is clinical worsening. Areas of general consensus include when and how respiratory cultures should be performed, what information should be reported, and when AST should be performed. A key finding is that clinical response to treatment is used to guide treatment decisions rather than AST results.<h4>Conclusions</h4>Recommendations are presented regarding questions related to microbiology testing for patients with CF. We have also offered recommendations for priority research questions. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Elsevier BV |
|
dc.relation.ispartofseries |
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
Antimicrobial Resistance International Working Group in Cystic Fibrosis |
|
dc.subject |
Humans |
|
dc.subject |
Cystic Fibrosis |
|
dc.subject |
Anti-Bacterial Agents |
|
dc.subject |
Treatment Outcome |
|
dc.subject |
Microbial Sensitivity Tests |
|
dc.subject |
Consensus |
|
dc.subject |
Drug Resistance, Bacterial |
|
dc.subject |
Patient Selection |
|
dc.subject |
International Cooperation |
|
dc.subject |
Delphi Technique |
|
dc.subject |
Adult |
|
dc.subject |
Child |
|
dc.subject |
Critical Pathways |
|
dc.subject |
Procedures and Techniques Utilization |
|
dc.subject |
Antimicrobial resistance |
|
dc.subject |
Biotechnology |
|
dc.subject |
Lung |
|
dc.subject |
Rare Diseases |
|
dc.subject |
Infectious Diseases |
|
dc.subject |
Prevention |
|
dc.subject |
Clinical Research |
|
dc.subject |
Pediatric |
|
dc.subject |
Infection |
|
dc.subject |
Congenital |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Respiratory System |
|
dc.subject |
ERADICATION |
|
dc.subject |
MRSA |
|
dc.subject |
1102 Cardiorespiratory Medicine and Haematology |
|
dc.subject |
Health services & systems |
|
dc.subject |
Clinical Medicine and Science |
|
dc.subject |
Congenital Disorders |
|
dc.subject |
1103 Clinical Sciences |
|
dc.title |
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1016/j.jcf.2019.10.006 |
|
pubs.issue |
3 |
|
pubs.begin-page |
370 |
|
pubs.volume |
19 |
|
dc.date.updated |
2022-05-26T02:49:26Z |
|
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
31680041 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/31680041 |
|
pubs.end-page |
375 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
|
pubs.subtype |
Journal Article |
|
pubs.subtype |
Research Support, N.I.H., Extramural |
|
pubs.elements-id |
786486 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
School of Medicine |
|
pubs.org-id |
Paediatrics Child & Youth Hlth |
|
dc.identifier.eissn |
1873-5010 |
|
dc.identifier.pii |
S1569-1993(19)30919-1 |
|
pubs.record-created-at-source-date |
2022-05-26 |
|